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Abstract: The Mediterranean marine sponge Crambe crambe is the source of two families 
of guanidine alkaloids known as crambescins and crambescidins. Some of the biological 
effects of crambescidins have been previously reported while crambescins have undergone 
little study. Taking this into account, we performed comparative transcriptome analysis to 
examine the effect of crambescin-C1 (CC1) on human tumor hepatocarcinoma cells 
HepG2 followed by validation experiments to confirm its predicted biological activities. 
We report herein that, while crambescin-A1 has a minor effect on these cells, CC1 protects 
them against oxidative injury by means of metallothionein induction even at low 
concentrations. Additionally, at high doses, CC1 arrests the HepG2 cell cycle in G0/G1 
and thus inhibits tumor cell proliferation. The findings presented here provide the first 
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detailed approach regarding the different effects of crambescins on tumor cells and provide 
a basis for future studies on other possible cellular mechanisms related to these bioactivities. 
Keywords: crambescin-C1; crambescin-A1; metallothionein; Crambe crambe; sponge-derived 
compounds; transcriptome profiling; antioxidant effect; cell cycle inhibition 
 
1. Introduction 
In the past few years the marine environment has proved to be an important source of bioactive 
natural compounds. Since the fifties, a scientific enthusiasm for these products has emerged due to 
their extraordinary richness and originality [1,2]. Marine natural compounds are synthesized through 
the secondary metabolism of marine organisms and are of particular interest for pharmaceutical 
applications due to their biological activities [1,3–7]. 
Among marine invertebrates, Porifera (sponges), constitutes one of the most studied phyla owing to 
their capacity to produce original metabolites [8]. Since the isolation of spongothymidine and 
spongouridine in 1951 [9], a significant number of sponge secondary metabolites were isolated and 
identified as antitumoral, anti-inflammatory, antimicrobial, antifungal and antiviral compounds [10]. 
The noticeable examples of the sponge-derived arabinosilcytosine (Ara-C), currently approved for 
clinical use in the treatment of acute myeloid leukemia and non-Hodgkin’s lymphoma [11,12], as well 
as eribulin mesylate, approved by the US Food and Drug Administration for the treatment of 
metastatic breast cancer; highlight the importance of research on these natural products. Therefore, the 
increasing interest in the study of their bioactivities is fully understandable. 
Crambe crambe mainly produces two families of compounds called crambescins and  
crambescidins [13,14]. Crambescins are mono- or bi-cyclic guanidinic alkaloids firstly isolated from 
this encrusting Mediterranean sponge [15–17]. 
The available data on the bioactivity of crambescidins indicate that crambescidin 816 (C816) and 
crambescidin 800 (C800) possess cytotoxic, antifungal, antioxidative, antimicrobial and antiviral 
activities [18–24]. C816 also exerts a potent Ca2+ antagonist activity, even more intense than 
nifedipine, a selective blocker of L-type Ca2+ channels [14]. Moreover, we have previously evaluated 
the cytotoxic activity of C816 over several human tumor cell types and characterized some of  
the cellular mechanisms responsible of the anti-proliferative effect of C816 on human liver-derived  
tumor cells [24]. 
While the biological effects of crambescidins have been widely investigated, in the case of 
crambescins very few data are available. In order to tackle this lack of knowledge and to establish if 
these compounds could have interest as drugs leads, we examined the effect of crambescin-C1 (CC1) 
and crambescin-A1 (CA1) on human tumor hepatocarcinoma cells HepG2. According to this, 
comparative gene expression profiles following CC1 treatment were firstly performed. Obtained 
results showed that up-regulation of metallothionein mRNA was one of the major cellular responses to 
CC1. Besides this, effects on cell cycle progression and cellular antioxidant response were also 
observed. Comparative transcriptome analysis results were then backed up with assays which 
confirmed the biological effects inferred from them.  
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2. Results and Discussion 
2.1. CC1 Inhibits Cell Proliferation and Induces Cell Death at High Doses 
In order to establish the appropriate concentrations to perform transcriptome analysis, we initially 
assayed the effects of CC1 and CA1 (Figure 1A) on HepG2 cells growth and viability. 
The 3-(4,5-dimethylthiazol-2-l)-2,5-diphenyltetrazolium bromide (MTT) assays showed that  
after 24 h CC1 reduced cell viability by approximately 33% only at the highest concentration tested  
(Figure 1B). While no effect was observed after 24 h, an inhibition percentage of 22% was caused by  
5 μM CC1 after 48 h (Figure 1B). 
Similar doses of CA1 did not reduce cell proliferation whatever the length of the exposure (Figure 1C). 
Interestingly, CA1’s lack of ability to reduce cellular growth refuted the possibility of a broad 
crambescin family effect in this regard. 
 
Figure 1. (A) Structure of crambescin C1 (CC1) and crambescin A1 (CA1);  
(B) Proliferation of HepG2 cells after CC1 treatment for 24 and 48 h; (C) Proliferation of 
HepG2 cells after CA1 treatment for 24 h and 48 h. In both cases cellular growth was 
determined by the 3-(4,5-dimethylthiazol-2-l)-2,5-diphenyltetrazolium bromide (MTT) 
method. * Significant differences respect to controls, p < 0.05, n = 3. 
CC1 induced apoptosis in HepG2 cells as determined by Annexin V and propidium iodide (IP) 
staining. While no apoptosis was detected after 24 h treatment with 1 μM and 5 μM CC1, 10 μM 
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induced phosphatidylserine translocation. A slight increase of the apoptotic population was also detected 
after 48 h exposure to 5 μM CC1. Therefore, CC1 induced HepG2 cell apoptosis as a factor of time and 
dose exposure (Figure 2). 
 
Figure 2. Apoptosis detection by confocal microscopy after 24 h and 48 h treatments  
with 1, 5 and 10 μM crambescin C1 (CC1). Representative photos of control and treated 
cells are shown. Fluorescein isothiocyanate (FITC) was used for phosphatidylserine 
translocation detection (green) and propidium iodide (IP) was used for nuclei staining of 
death cells (red). 
Taking these results into account, just CC1 was selected to perform transcriptome analysis. 
Concentrations of 1 μM, 5 μM and 10 μM were tested since the highest one induced apoptosis after 24 h. 
This effect was not observed for 5 μM CC1 but after 48 h. Finally, a non-inhibitory concentration was 
selected to detect which gene expression variations, if any, were not related to cell death induction. 
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2.2. Transcriptional Alterations Induced by CC1 on HepG2 Cells 
Transcriptomic data analysis showed that, after 24 h, CC1 significantly affected gene expression at  
5 μM and 10 μM. These concentrations induced 56 and 617 genes and repressed another 658 and 750 
genes respectively (Figure 3A). Gene ontology analysis of up- and down-regulated biological 
processes showed that 5 μM CC1 repressed genes involved in blood coagulation, transport and 
metabolism of amino acids and lipids. At the same concentration, CC1 induced genes regulating cell 
homeostasis and genes implicated in cellular response to extracellular stimulus, inorganic substances and 
cold (Figure 3B). At 10 μM, CC1 repressed genes involved in cell cycle, coagulation regulation, DNA 
replication, and oxidation/reduction processes, while inducing genes related to lipid metabolism and 
gene expression regulation (Figure 3C). 
To compare gene expression patterns of repressed genes, a Venn diagram was used since the lowest 
concentration induced few genes when compared to the highest one. Both concentrations repressed 
163 genes while more than 500 genes were independently repressed by each of them (Figure 4A). 
According to Keggs pathway analysis, shared genes with the highest enrichment scores are involved in 
drug and xenobiotic metabolism. Other processes like lipid, retinoid acid, tyrosine, glutathione, linoleic 
acid, bile acid, and steroid hormone metabolism and/or biosynthesis, although significant, presented 
lower enrichment scores (Figure 4B). Genes down-regulated by 10 μM CC1, which were not affected 
in cells treated with 5 μM CC1, are tied to cell cycle control and progression, DNA replication and 
cellular adhesion (Figure 4C). Genes exclusively down-regulated by 5 μM CC1 are involved in drug, 
xenobiotic, sugar and lipids metabolisms (Figure 3D). Even though 5 μM CC1 treatment induced few 
genes, it shared with the 10 μM treatment the induction of metallothioneins (MTs) 1 and 2 (Figure 4E). 
Therefore, induction of metallothionein expression was a widespread response of HepG2 cells to  
CC1 exposure. 
Metallothioneins are a family of low-molecular weight (6–7 kDa), cysteine-rich intracellular 
proteins with a well-known metal-binding property [25–27]. There are ten human MT isoforms which 
are jointly encoded by four gene families (MT-1, MT-2, MT-3 and MT-4) grouped at a single locus on 
chromosome 16q13 [28,29]. The two major isoforms (MT-1 and MT-2) are ubiquitously expressed 
within tissues while the two minor (MT-3 and MT-4) are mostly found in the central nervous system 
and stratified squamous epithelia, respectively [30–32]. 
MT-1 and -2 are the most abundant isoforms in human hepatic cells and are also predominant in the 
human hepatoma cell line HepG2 [33]. Although MT is down-regulated in hepatocellular carcinoma [34], 
HepG2 cells preserve their capacity to synthesize it in response to diverse stimuli [35,36]. The results 
presented in this work provide the first evidence that exposure to CC1 causes an up-regulation in MT-1 
and MT-2 isoforms expression. MTs levels increase in response to diverse oxidative stress agents, such 
as glucorticoids, heavy metals and inflammatory signals, indicating that these proteins are tied to 
pathways involved in cellular response to oxidative damage [37–40]. In fact, there are two different 
cysteine clusters within the MT molecule, one closer to the N-terminal part designated as β-domain 
and other closer to the C-terminal part known as α-domain. [41,42]. These cysteinyl thiolate groups 
provide the chemical basis by which MTs can bind metal atoms and function as antioxidants against 
reactive oxygen and nitrogen species [43]. 
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Cells possess an antioxidant defense system formed by enzymes and other major antioxidants such 
as reduced glutathione (GSH) [44]. MTs are now understood as part of the defense system since  
in vitro studies confirmed their ability as free radical scavengers [45,46]. Enhanced susceptibility to 
damage caused by oxidant agents, as for example cadmium or nitric oxide, has been proved in cells 
with a deficiency in some MTs isoforms [47–49]. Similarly, resistance against free radical damage due 
to MTs overexpression has been documented in cells and tissues [50–52]. To determine if the 
increment of MT expression produced by CC1 affected the redox status of HepG2 cells, we further 
investigated the effect of this molecule on cells exposed to an oxidant insult. 
 
Figure 3. (A) Induced and repressed genes after 24 h treatment of HepG2 cells with 
crambescin C1 (CC1), determined by microarray analysis; (B) Biological processes 
significantly altered in 5 μM CC1 treated HepG2 cells, determined by ontological analysis 
of up- and down-regulated genes. Dashed bars: up-regulated biological processes. Dotted 
bars: down-regulated biological processes; (C) Biological processes significantly altered in 
10 μM CC1 treated HepG2 cells, determined by ontological analysis of up- and  
down-regulated genes. Dashed bars: up-regulated biological processes. Dotted bars:  
down-regulated biological processes. 
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Figure 4. (A) Venn diagram for the down-regulated mRNAs in HepG2 cells treated with 5 
and 10 μM crambescin C1 (CC1) for 24 h; (B) Pathways repressed by CC1 at both 
concentrations tested, as determined by Kyoto Encyclopedia of Genes and Genomes 
(KEGGS) pathways; (C) Pathways repressed by 10 μM CC1 as determined by KEGGS 
pathways; (D) Pathways repressed by 10 μM CC1 as determined by KEGGS pathways. In 
all cases an enrichment p-value from modified Fisher’s Exact test (EASE Score) <0.05 was 
selected for significant pathway identification; (E) Graph showing the relative increment of 
metallothionein expression in CC1 treated cultures respect to controls. Shown increments 
were identified as significant after microarray analysis, p < 0.05, n = 3. 
2.3. CC1 Arrests HepG2 Cell Cycle in G0/G1 
As initially determined by MTT, CC1 inhibits cell proliferation. Microarrays results showed that 
CC1 negatively affected the cell cycle progression down-regulating the expression of cyclins A, B, D, 
and E (Figure 5A,B). According to this, a G0/G1 arrest could be expected. 
To confirm this possibility, HepG2 cells were treated with 0.3 μM, 1 μM, 5 μM and 10 μM CC1 for 
24 h and analyzed by flow cytometry. CC1 did not cause any significant restriction of the cell cycle 
progression at 0.3 μM, 1 μM and 5 μM (Figure 5C). However, at 10 μM it produced a significant 
G0/G1 arrest and decreased the cellular populations in the S and G2/M phases (Figure 5C,D). These 
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results agree with those formerly obtained by the MTT assay on HepG2 cells treated with the same 
CC1 concentrations for 24 h. 
 
Figure 5. (A) Heat map of the differentially expressed (DE) mRNAs coding for proteins 
involved in cell cycle regulation in HepG2 cells treated with 1 μM, 5 μM and 10 μM 
crambescin C1 (CC1) with respect to control cells. Green color represents mRNA  
down-regulation of treated cells with respect to controls; (B) Centroid graph for  
down-regulated genes showed in A. * Significant differences with respect to controls and  
5 μM treated cells, p < 0.05, n = 3; (C) Quantification of the cell population percentages in 
each phase of the cell cycle in control and HepG2 cells treated with 0.3 μM, 1 μM, 5 μM and 
10 μM CC1 for 24 h. (p < 0.01, n = 2); (D) Analysis of the relative fluorescence intensity of 
the stained nuclei. Histograms indicate the differences in the relative proportions of cells in 
G0/G1 and G2/M phases between control and 10 μM CC1 treated cells. 
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MTT assays showed that, after 48 h, CC1 produced a slight decrease in cell proliferation at 5 μM 
and had no significant effect at 1 μM. To detect a moderate decrease in cell proliferation it was 
necessary to increase CC1 concentration until 10 μM for 24 h. Microarray analysis showed that, at this 
concentration, CC1 negatively affected the cell cycle progression decreasing the expression of cyclins 
A, B, D, and E. These changes in gene expression are in concordance with the G0/G1 cell cycle arrest 
detected by flow cytometry after cell treatment with 10 μM CC1 for 24 h [53,54]. Therefore, results 
demonstrated than the inhibition of the cell cycle progression caused by CC1 ultimately results from 
changes in the expression of cell cycle-regulatory proteins. Although MTs levels increase does not 
explain the cell cycle arrest caused by CC1 on HepG2 cells, we cannot exclude their possible 
implication if we take into account that some studies have suggested the existence of a relationship 
between MTs and proteins involved in cell cycle control [55,56]. 
2.4. CC1 Protects Cells against Oxidative Injury 
Considering that oxidative stress is a well-known inducer of MTs transcription [57], CC1’s effect 
on reactive oxygen species (ROS) generation was initially assayed by the 7′,2′-dichlorofluorescein 
diacetate (DCFH-DA) method. After 48 h exposure, CC1 did not increase ROS production on HepG2 
cells at 1 μM and 5 μM (Figure 6A). The same results were obtained for CA1 (Figure 6B). 
Because CC1 induced an up-regulation in MTs expression, its capacity to protect cells against 
oxidative damage was tested. Co-incubations of the natural compound with terbutil-hydroperoxide  
(t-BHP) were done as previously described, and ROS production was measured. CC1 diminished 
cellular ROS formation caused by t-BHP compared with cells just treated with t-BHP (Figure 6A). The 
decreases were significant for all the concentrations tested in a dose-response manner, and the 
reduction of ROS production was more pronounced at 5 μM. Moreover, significant differences 
between treatments were detected. 
We have demonstrated that CC1 is able to protect cells against t-BHP-caused injury while, in the 
case of CA1, no effect was observed. Results suggest that the up-regulation in MTs expression and the 
increment of the MT-1, -2 isoforms synthesis induced by CC1 may be strongly linked to the protective 
antioxidant response caused by this compound after long-term treatments (48 h). 
Western blot analysis results obtained after cells treatment with 5 μM CC1 for 48 h confirmed that, 
at this concentration, CC1 caused a significant increase in MT-1, -2 levels. For the same period of time 
(48 h) the increments produced by 10 μM CC1 were even higher. At these concentrations significant 
changes were only detected after 24 h cellular exposure to 10 μM CC1 (Figure 6D,E). 
As expected, no antioxidant effect was observed for CA1 (Figure 6B). These results supported those 
previously obtained with the MTT assays and confirmed that, with regard to its biological activity, 
CA1 had a minor effect on HepG2 cells. Accordingly, no additional experiment was performed with  
this compound. 
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Figure 6. (A) Measurement of reactive oxygen species (ROS) generation and evaluation of 
the HepG2 antioxidant response after 48 h treatment with 1 μM and 5 μM crambescin C1 
(CC1); (B) Measurement of ROS generation and evaluation of the HepG2 antioxidant 
response after 48 h treatment with 1 μM and 5 μM CA1; (C) Cellular level of reduced 
glutathione in HepG2 cells treated with 1 μM and 5 μM CC1 for 48 and 72 h; (D) Western 
blot analysis of soluble MT-1 and -2, CAT, SOD, Nfr2 and anti-β-tubulin (TUBB, reference 
for loading normalization) levels in HepG2 cells treated with 5 μM and 10 μM CC1 for 24 h 
and 48 h. Representative images are shown. Three experiments were performed for each 
analyzed protein; (E) Quantification of the differences in protein levels among control, 5 μM 
and 10 μM CC1 treated cells. * Significant differences with respect to controls, p < 0.05. 
Many cytoprotective enzymes induced in response to oxidative stress are regulated primarily at the 
transcriptional level [58]; for this reason we carefully analyzed transcriptomic data looking for other 
alterations related with pathways involved in the cellular antioxidant response. Superoxide dismutase 
and catalase are two major enzymes in this response; likewise, nuclear factor (erythroid-derived 2)-like 2 
(Nrf2) is a transcription factor activated by ROS which controls transcription of genes encoding these 
detoxification enzymes [59]. 
Data revealed that, even at 10 μM, no variation was observed in these cellular mechanisms after  
24 h exposure to CC1. 
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Although gene expression of SOD, CAT and Nrf2 was not affected, we performed western blot 
analysis to rule out protein increases. No variations were detected in relation to control cells after 24 h 
or 48 h (Figure 6D,E). These results further support the role of MTs in the protection against oxidative 
stress produced by CC1 on HepG2 cells and point to these proteins as the major agents responsible of 
this effect. 
To further clarify the cause of the antioxidant protection produced by CC1, its influence on GSH 
levels was investigated. GSH is part of the cellular defense systems against oxidative injury. CC1 
produced a slight decrease in GSH levels after 48 h treatment with 5 μM while no effect was observed 
at 1 μM. Results obtained after 72 h demonstrated that longer exposures to 5 μM CC1 did not cause a 
major reduction in GSH; conversely, there was a complete reestablishment of GSH to control levels. 
Finally, when cells were exposed to 1 μM CC1 for 72 h a significant decrease in GSH levels was 
produced (Figure 6C). 
GSH contributes to maintain the thiol/disulfide redox potential in cells by reacting with free 
radicals. It plays a role during phase II of xenobiotic metabolism and also functions as a glutathione 
peroxidase substrate [60,61]. We demonstrated that CC1 mildly decreased GSH levels on HepG2 cells 
after 48 h treatment. The lowest concentration tested (1 μM) did not produce any detectable effect over 
GSH levels until 72 h, a time at which cells exposed to 5 μM recovered normal GSH concentrations. 
At these concentrations the increment in MTs synthesis produced in response to CC1 seems to be 
enough to allow cell survival and retrieval in GSH levels. Previous in vivo and in vitro studies have 
documented the existence of a link between MT and GSH levels. In fact, they have demonstrated that 
MTs induction attenuates the effect of GSH depletors in hepatocytes [62,63]. MTs gene transcription 
induction in response to oxidative stress has been widely described before, also under conditions that 
did not reduce cell viability [57,64]. Furthermore, it has been previously established that hepatic levels 
of MTs are primarily determined at the transcriptional level [65]. 
Our results demonstrated that CC1 does not increase ROS formation in HepG2 cells, which means 
that the antioxidant response generated by this molecule is not triggered by ROS production. 
Additional studies are currently being undertaken to further investigate the mechanism by which this 
molecule induces MTs and protects cell against oxidative injury. 
CC1 Increases Nuclear MTs Levels 
Cellular MTs distribution pattern was assayed by confocal microscopy. HepG2 cells were treated 
with low concentrations of CC1 for 12 h in order to ensure the adequate conditions for the detection of 
the CC1 effect on MTs cellular levels while avoiding any interference with its growth inhibitory ability. 
Increased nuclear concentrations of MTs proteins were observed after treatments with 2.5 μM and  
5 μM CC1 when compared with the levels detected in untreated cells. Therefore, CC1 caused the 
translocation of MTs from cytoplasm to the nucleus (Figure 7A). To quantify this effect, cellular nuclei 
stained with Hoechst 33258 were delimitated and MTs fluorescence emission analyzed using the 
Image J software. Results showed significant increases in nuclear MTs levels in response to 2.5 μM 
and 5 μM CC1 (Figure 7B). 
MTs are mainly cytoplasmic proteins but they can migrate to the nucleus depending on the cell 
cycle phase or under certain conditions such as cell proliferation and differentiation [66–69]. Our 
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results demonstrated that even short-term treatments with CC1 caused a cellular translocation of MTs 
from cytoplasm to the nucleus. MTs are rapidly translocated to the nucleus in response to oxidative 
stress [70], where they seem to have an antimutagenic role [71]. Apart from ROS, another reactive 
species has proved to enhance nuclear localization of MTs to protect DNA [39,72]. 
 
Figure 7. (A) MT-1, -2 detection by confocal microscopy in control and HepG2 cells 
treated with 2.5 μM and 5 μM crambescin C1 (CC1) for 12 h. Representative photos of 
control and treated cells are shown. Hoechst 33258 was used for nuclei counterstaining 
(blue) and quantification of nuclear metallothioneins (MTs). Arrows: MTs translocation to 
the nucleus in treated cells; (B) Quantification of the variations caused by CC1 in the levels 
of nuclear MTs. 
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3. Experimental Section 
3.1. Reagents and Solutions 
Eagle’s Minimal Essential Medium (E-MEM), penicillin, streptomycin, anti-cytoplasmic superoxide 
dismutase, 3-(4,5-dimethylthiazol-2-l)-2,5-diphenyltetrazolium bromide (MTT), anti-catalase, anti-β-
tubulin, anti-rabbit and anti-mouse IgG horseradish peroxidase-linked species-specific whole 
antibodies, CY3-conjugated anti-mouse secondary antibody, Hoechst 33258, propidium iodide, Triton 
X-100, ethylenediaminetetraacetic acid (EDTA), sodium deoxycholate, sodium dodecyl sulfate (SDS), 
Tween® 20, sodium chloride (NaCl), trizma base, 7′,2′-dichlorofluorescein diacetate (DCFH-DA), 
terbutil-hydroperoxide (t-BHP) and bovine serum albumin (BSA) were purchased from Sigma-Aldrich 
(Madrid, Spain). Fetal bovine serum (FBS) was from Cambrex Corporation (Charles City, IA, USA). 
Aurum™ Total RNA Mini Kit and Precision Plus Protein™ Standards Kaleidoscope™ were obtained 
from Bio-Rad Laboratories (Barcelona, Spain). The RNA 6000 nano reagents kit was from Agilent 
Technologies (Madrid, Spain). The cDNA Synthesis System, the NimbleGen One-Color DNA 
Labeling Kit, the NimbleGen Hybridization Kit, the NimbleGen microarrays, the protease inhibitor 
complete tablets and the phosphatase inhibitor cocktail tablets were obtained from Roche (Madrid, 
Spain). Dulbecco’s Phosphate-Buffered Saline (D-PBS), Dulbecco’s Phosphate-Buffered Saline, 
calcium, magnesium (D-PBS C/M) and ThiolTracker™ Violet were from Gibco®, Thermo Fisher 
Scientific Corporation (Madrid, Spain). Polyvinylidene fluoride (PVDF) membranes and anti-nuclear 
factor (erythroid-derived 2)-like 2 antibody were purchased from Merck-Millipore (Temecula, CA, 
USA). SuperSignal® West Pico, SuperSignal® West Femto and anti-metallothionein antibody were 
from Thermo Fisher Scientific Corporation (Madrid, Spain). 
3.2. Crambescins Isolation 
Both CC1 and CA1 were purified following the protocol proposed by [17] using a specimen of the 
sponge C. crambe sampled in the bay of Villefanche-sur-Mer (Villefanche-sur-Mer, France). The 
compounds were identified by both ultraperformance liquid chromatography-high resolution mass 
spectrometry (UPLC-HRMS) and Nuclear Magnetic Resonance spectroscopy (NMR) analysis (95% 
purity) and were then dissolved in dimethyl sulfoxide (DMSO). The final DMSO concentration for cell 
treatment was always lower than 0.2%. 
3.3. Cell Culture 
HepG2 cell line was purchased from the American Type Culture Collection (ATCC) and cultured in 
E-MEM supplemented with 10% fetal bovine serum, 100 UI/mL penicillin and 0.1 mg/mL 
streptomycin, at 37 °C in a humidified 5% CO2 atmosphere. 
3.4. Cell Viability Assays 
Cells were seeded in 96 well plates at a density of 8000 cells/well and incubated overnight before 
treatment. They were then exposed to different concentrations of CC1 and CA1 for 24 h and 48 h. 
Viability was determined by the MTT method following the manufacturer’s instructions and 
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absorbance was measured at 570 nm and 670 nm using a Bio-Tek Sinergy plate reader. For each 
treatment three experiments with n = 8 were performed. 
3.5. Apoptosis Determination 
Cells were cultured on poly-lysine coated cover slips at a density of 400,000 cells/well and treated 
with 1 μM, 5 μM and 10 μM CC1 for 24 h and 5 μM CC1 for 48 h. After washing twice with 
temperate PBS cover slips were maintained in Annexin binding buffer and stained with Annexin  
V-FITC and propidium iodide (1%) at room temperature for 15 min in the dark. Two more washes 
with Annexin binding buffer were made before image acquisition. Stained cells were analyzed with a 
NIKON-TE2000-3 confocal microscope (Nikon; Amsterdam, Netherlands). Each condition was tested 
in duplicate and three experiments were done. Representative images of each condition are presented 
in this work. 
3.6. Microarrays Assay and Analysis 
To obtain RNA for microarray assays, HepG2 cells were treated with CC1 and CA1 for 24 h. RNA 
from control and treated cells was purified using the Aurum™ Total RNA Mini Kit following the 
manufacturer’s instructions. Concentration and integrity were determined with a NanoDrop 2000 
(Thermo Fisher Scientific) and with a Bioanalyzer 2100 (Agilent) using the RNA 6000 nano reagents 
kit respectively. 
cDNA was synthesized using the cDNA Synthesis System and labeled with the NimbleGen  
One-Color DNA Labeling Kit following manufacturer’s instructions. Five μg of labeled cDNA from 
each sample were hybridized onto NimbleGen microarrays (100718_HG18_opt_expr_HX12) using the 
NimbleGen Hybridization Kit in a NimbleGen HS4 mixer (Roche). After washing and drying, 
microarrays were scanned with a NimbleGen MS200 scanner (Roche). Scanned images were extracted 
and bursted using the DEVA 1.2.1 software (Roche). The same software was used for data 
normalization using robust mass analysis (RMA). For the analysis of differential gene expression, 
normalized data was loaded in the TM4 Microarray Software Suite [73,74]. Gene lists were analyzed 
for differentially expressed (DE) genes using the statistic tool SAM (Significance Analysis of 
Microarrays) and a false discovery rate (FDR) of 5%. Data mining for significant altered metabolic 
pathways and ontological categories at the biological process level 5 was performed with the DAVID 
Bioinformatics Database [75,76]. 
3.7. Antioxidant Activity Assay 
Free radical formation was quantified using the non-polar compound 7′,2′-dichlorofluorescein 
diacetate (DCFH-DA). Once deacetylated, this compound is trapped within the cell and oxidized to the 
fluorescent 7′,2′-dichlorofluorescein (DCF) in the presence of an oxidant. Cells treated with 1 μM and  
5 μMT CC1, as well as control cells, were loaded with 20 μM DCFH-DA for 30 min at 37 °C. After 
that, cells were rinsed twice with fresh medium and 0.1 mM terbutil-hydroperoxide (t-BHP) was added 
to corresponding wells for one hour. Finally, fluorescence intensity was measured using a Bio-Tek 
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Sinergy plate reader with excitation wavelength set at 495 nm and emission wavelength set at 530 nm. 
Each condition was tested with n = 4 and three experiments were performed. 
3.8. Glutathione Quantification 
To estimate the cellular level of reduced glutathione, HepG2 cells were seeded on poly-lysine 
coated 96 well plates at a density of 8000 cells/well and labeled with ThiolTracker™ Violet dye. 
In brief, once cells had been treated with 1 and 5 μM CC1 for 24 and 48 h the incubation medium 
was removed from the wells and cells were rinsed twice with D-PBS C/M. A pre-warmed 20 μM 
solution of ThiolTracker™ Violet dye in D-PBS C/M was added to each well and the plates were 
incubated for 1 h at 37 °C. Finally, cells were rinsed once more with D-PBS and fluorescence was 
determined at 404 nm excitation and 526 nm emission using a Bio-Tek Sinergy plate reader. For each 
treatment three experiments with n = 4 were carried out. 
3.9. Western Blot Analysis 
Control and CC1 treated cells were re-suspended in RIPA lysis buffer (150 mM NaCl, 1% Triton  
X-100, 0.5% sodium deoxycholate, 0.1% SDS and 50 mM Tris, pH = 8) and kept on ice for 30 min. 
Once lysed, cells were centrifuged (15 min at 14,000 rpm, 4 °C) and supernatants were recovered. A 
Direct Detect™ spectrometer (Merk-Millipore) was used to quantify protein concentration in the 
lysates and equivalent amounts of protein were resolved by SDS-PAGE and transferred to PVDF 
membranes. 
PVDF membranes were blocked overnight with a solution of 3% non-fat milk and incubated with 
primary antibodies (anti-cytoplasmic superoxide dismutase (SOD) 1:1000, anti-catalase (CAT) 1:1000, 
anti-nuclear factor (erythroid-derived 2)-like 2 (Nrf2) 2:1000, anti-β-tubulin (TUBB) 1:5000,  
anti-metallothionein (MT1-2) 1:1000) for 3 h at room temperature. Then three washed with PBS-0.1% 
Tween® 20 were made and membranes were incubated again for 1 h at room temperature with 
secondary anti-rabbit and anti-mouse IgG horseradish peroxidase-linked antibodies. Washed membranes 
were revealed with SuperSignal® West Pico or SuperSignal® West Femto using a Diversity detector 
(Syngene; Cambridge, UK). Protein expression was normalized with β-tubulin and differences 
between treatments were determined with the image analysis software GeneTools (Syngene; 
Cambridge, United Kingdom). 
3.10. Cell Cycle Assay by Flow Cytometry 
Control and CC1 treated cells were detached from the plates with 0.25% trypsin and 0.2% EDTA 
and washed twice with 0.1% BSA and 0.3 mM EDTA in PBS. Cells were fixed in cold 70% ethanol. 
Samples were maintained at 4 °C for 30 min and then washed twice with PBS before staining. After 
centrifugation, supernatants were discarded and pellets labeled with 50 μL of Telford reagent (75 μM 
IP, 0.1 mM EDTA, 1.34 mg RNase, 0,1% Triton X-100). Cells were incubated at room temperature for 
1 h protected from the light. 
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An ImageStream® cytometer was used to process the samples and obtained data were analyzed 
using the IDEAS® Cell Image Analysis software. All conditions were tested in triplicate and for each 
replicate a total number of 5000 events were acquired. Two experiments were performed. 
3.11. Confocal Microscopy 
HepG2 cells were cultured on poly-lysine coated cover slips and treated with CC1 for 12 h. Treated 
cells were fixed with 4% paraformaldehyde for 15 min at 4 °C. Then, cells were permeabilized with a 
solution of 0.2% Triton X-100 in PBS and washed 3 times with PBS-0.1% Tween® 20 before labeling. 
Cover slips were incubated with an anti-metallothionein-1 and -2 antibody dissolved in a solution of 
2% BSA in PBS for 1 h at room temperature. Cells were then washed 3 times and incubated again with 
1:500 CY3-conjugated anti-mouse secondary antibody for 1 h protected from light. Before mounting, 
cover slips were rinsed with PBS-0.1% Tween® 20 another 3 times and 1 μM Hoechst 33258 was 
added in the last wash for nuclei counterstaining. 
Images were obtained with a NIKON TE2000-3 confocal microscope and analyzed using the image 
processing software Image J. For each treatment representative images were obtained and are 
presented in this work.  
3.12. Statistics 
The results were analyzed using the SIGMAPLOT® software. One-way analysis of variance 
(ANOVA) was used to test for differences among groups and the Holm-Sidak multiple-range test was 
used for multiple comparisons between groups. A p < 0.05 was considered significant. 
4. Conclusions 
The results presented in this work demonstrate that CC1 can induce MTs transcription and synthesis 
in the human hepatocarcinoma cell line HepG2, protecting cells from oxidative damage at 
concentrations that do not reduce cell viability. At high doses, it produces a significant decrease in cell 
viability and also arrests cell cycle progression at the G0/G1 phase. These findings provide the first 
detailed approach regarding the different bioactivities of crambescins on tumor cells and provide a 
basis for future studies. We are currently performing further experiments to elucidate the cellular 
mechanisms underlying these effects. 
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